Equities analysts expect Nuvectra Corp (NASDAQ:NVTR) to post earnings of ($0.86) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Nuvectra’s earnings, with the lowest EPS estimate coming in at ($1.03) and the highest estimate coming in at ($0.74). Nuvectra reported earnings of ($0.80) per share during the same quarter last year, which suggests a negative year over year growth rate of 7.5%. The business is scheduled to report its next earnings results on Tuesday, March 5th.
On average, analysts expect that Nuvectra will report full year earnings of ($3.41) per share for the current financial year, with EPS estimates ranging from ($3.62) to ($3.27). For the next fiscal year, analysts forecast that the company will report earnings of ($2.80) per share, with EPS estimates ranging from ($2.86) to ($2.70). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Nuvectra.
Nuvectra (NASDAQ:NVTR) last issued its quarterly earnings results on Monday, October 29th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.01). The firm had revenue of $14.22 million for the quarter, compared to analysts’ expectations of $12.38 million. Nuvectra had a negative return on equity of 65.86% and a negative net margin of 87.94%.
Shares of NASDAQ NVTR opened at $19.97 on Friday. The stock has a market cap of $351.65 million, a PE ratio of -4.73 and a beta of -0.37. Nuvectra has a 12 month low of $7.60 and a 12 month high of $25.17. The company has a quick ratio of 7.35, a current ratio of 7.63 and a debt-to-equity ratio of 0.42.
In related news, President Joseph Paul Hanchin sold 1,600 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $18.18, for a total value of $29,088.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.60% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in NVTR. First Manhattan Co. bought a new position in Nuvectra in the second quarter worth approximately $102,000. Metropolitan Life Insurance Co. NY purchased a new position in shares of Nuvectra in the 2nd quarter valued at $105,000. MetLife Investment Advisors LLC purchased a new position in shares of Nuvectra in the 2nd quarter valued at $148,000. GSA Capital Partners LLP purchased a new position in shares of Nuvectra in the 3rd quarter valued at $201,000. Finally, Financial Architects Inc grew its position in shares of Nuvectra by 300.0% in the 2nd quarter. Financial Architects Inc now owns 10,000 shares of the company’s stock valued at $205,000 after buying an additional 7,500 shares during the last quarter. Hedge funds and other institutional investors own 77.81% of the company’s stock.
Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.
Featured Article: Intrinsic Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.